SNOW DAVID B JR 4

What Happened

• David B. Snow Jr, a director of Teladoc Health, converted 28,986 restricted stock units (RSUs) into shares on May 20, 2026 (reported as a derivative exercise/conversion) and is reported as receiving a grant of 30,441 RSUs on May 21, 2026. Both transactions show $0.00 per share and $0 total cash consideration, consistent with RSU vesting/settlement and awards rather than open-market purchases or sales.

Key Details

• Transaction dates and types:
  • 2026-05-20: Exercise/conversion of derivative — 28,986 RSUs converted (acquired), also reported as disposed at $0.00 (derivative).
  • 2026-05-21: Grant/award (A) — 30,441 RSUs awarded at $0.00.
• Prices/values: all entries report $0.00 per share and $0 total cash consideration.
• Shares owned after transaction: the filing does not disclose a total post-transaction share count in the provided items.
• Notable footnotes:
  • F1/F4: Each RSU converts one-for-one into TDOC common stock (contingent right to one share).
  • F2: Shares are held of record by the David B. Snow, Jr. Irrevocable Trust (for the benefit of his children; spouse is trustee).
  • F3: The 28,986 RSUs were originally granted May 22, 2025 and vested in full May 20, 2026.
  • F5: The 30,441 RSUs vest on the earlier of May 21, 2027 or the day before Teladoc's 2027 annual meeting.
• Timeliness: Form 4 was filed 2026-05-21 for transactions on 2026-05-20 — not indicated as late.

Context

• These entries reflect RSU vesting/settlement and a subsequent RSU award. RSUs are compensation vehicles (not open-market purchases) and commonly report $0.00 per share on conversion/award lines.
• The filing’s disposal line at $0.00 likely reflects settlement mechanics (per footnotes showing trust treatment and RSU conversion) rather than a market sale. As always, awards/vestings are compensation events and do not, by themselves, indicate an insider buying or selling shares in the open market.